Quote:

The most common Covid-19 contact in antibody positive (versus negative) children was their teacher (21% vs. 12%; P= 0.022), a household relative (11% vs. 2%; P<0.001), a classmate (9 % vs. 4%; P= 0.03), followed by a home caregiver (4% vs. 0.1%; P<0.001). Sources with the greatest likelihood of possible contagion in students were: a home caregiver (OR: 27.9), a household relative (OR: 5.4), a classmate (OR: 3.2), and teacher (OR: 2.2).

Quote:

Transmission17 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs primarily via respiratory droplets from face-to-face contact and, to a lesser degree, via contaminated surfaces. Aerosol spread may occur, but the role of aerosol spread in humans remains unclear. An estimated 48% to 62% of transmission may occur via presymptomatic carriers.

Quote:

The mean (interquartile range) incubation period (the time from exposure to symptom onset) for COVID-19 is approximately 5 (2-7) days.43,44 Approximately 97.5% of individuals who develop symptoms will do so within 11.5 days of infection.43 The median (interquartile range) interval from symptom onset to hospital admission is 7 (3-9) days.45 The median age of hospitalized patients varies between 47 and 73 years, with most cohorts having a male preponderance of approximately 60%.44,46,47 Among patients hospitalized with COVID-19, 74% to 86% are aged at least 50 years.45,47

Quote:


Although only?approximately?25% of infected patients have comorbidities, 60% to 90% of hospitalized infected patients have comorbidities.45-49 The most common comorbidities in hospitalized patients include hypertension (present in 48%-57% of patients), diabetes (17%-34%), cardiovascular disease (21%-28%), chronic pulmonary disease (4%-10%), chronic kidney disease (3%-13%), malignancy (6%-8%), and chronic liver disease (<5%).45,46,49

Quote:

Several serological tests can also aid in the diagnosis and measurement of responses to novel vaccines.62,65,66 However, the presence of antibodies may not confer immunity because not all antibodies produced in response to infection are neutralizing.

Quote:

More than 200 trials of chloroquine/hydroxychloroquine, compounds that inhibit viral entry and endocytosis of SARS-CoV-2 in vitro and may have beneficial immunomodulatory effects in vivo,79,80 have been initiated, but early data from clinical trials in hospitalized patients with COVID-19 have not demonstrated clear benefit.81-83

Quote:

A clinical trial of 150 patients in China admitted to the hospital for mild to moderate COVID-19 did not find an effect on negative conversion of SARS-CoV-2 by 28 days (the main outcome measure) when compared with standard of care alone.83

Quote:

Are masks effective at preventing spread?

Yes. Face masks reduce the spread of viral respiratory infection. N95 respirators and surgical masks both provide substantial protection (compared with no mask), and surgical masks provide greater protection than cloth masks. However, physical distancing is also associated with substantial reduction of viral transmission, with greater distances providing greater protection. Additional measures such as hand and environmental disinfection are also important.

Turtle n Peeps wrote:



I would prefer they get all the facts and know what they are talking about before saying anything. (But that's just me)

I'm even ok with saying, "sorry, we can't release info because we don't know all the facts yet."

There is an old saying in race car racing and flying airplanes. "Guessing kills people."

The WHO was guessing back then.......and continue to do so.

In all fairness; so are a lot of Dr's.